Simulations Plus Wins Phase II Small Business Innovation Research Grant
News Apr 22, 2009
Simulations Plus, Inc. has announced that it was notified by the National Cancer Institute (NCI) that the company has been awarded a $525,000 Phase II Small Business Innovation Research (SBIR) grant.
The grant, which is disbursed over two years, is for Simulations Plus to further enrich the predictive capabilities of its best-in-class ADMET Predictor™ software product. ADMET Predictor is a software research tool used worldwide by pharmaceutical scientists to estimate absorption, distribution, metabolism, excretion, and toxicity properties of pharmaceutical compounds and to build advanced mathematical models.
Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics for Simulations Plus and principal investigator for the grant, said: “This Phase II grant extends the development and validation of our novel very fast method of calculating quantum atomic and molecular descriptors – important properties of new drug molecules that govern how they interact with each other and their environment.”
He continued, “The importance of the method we are developing cannot be overstated since these parameters are essential for accurate predictive modeling of molecular properties, especially in the areas of metabolism and toxicity. Independent comparison studies have shown ADMET Predictor models to be the most accurate in the world and we have now developed a novel method to further improve on them. Prior to our Phase I effort, calculating quantum descriptors of sufficient quality required enormous amounts of computer time.”
“In our Phase I effort we developed commercially valuable calculation methods that are orders of magnitude faster and yet accurate enough to provide improved prediction of a number of properties for new drug-like molecules. These calculations have already been commercially deployed in our latest release of ADMET Predictor and are in use by customers world-wide,” said Fraczkiewicz.
The primary objectives of the government’s SBIR program are to stimulate technological innovations in the private sector and to strengthen the role of small businesses in meeting federal research and development needs.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE